Literature DB >> 21691751

Assessing the value of CAN-gene mutations using MALDI-TOF MS.

Corina Kohler1, Björn Tavelin, Alex Xiu-Cheng Fan, Ramin Radpour, Zeinab Barekati, Fabio Levi, Xiao Yan Zhong, Per Lenner, Paolo Toniolo.   

Abstract

PURPOSE: To identify cancer-linked genes, Sjöblom et al. and Wood et al. performed a genome-wide mutation screening in human breast and colorectal cancers. 140 CAN-genes were found in breast cancer, which in turn contained overall 334 mutations. These mutations could prove useful for diagnostic and therapeutic purposes.
METHODS: We used a MALDI-TOF MS 40-plex assay for testing 40 loci within 21 high-ranking breast cancer CAN-genes. To confirm mutations, we performed single-plex assays and sequencing.
RESULTS: In general, the mutation rate of the analyzed loci in our sample cohort was very low. No mutation from the 40 loci analyzed could be found in the 6 cell lines. In tissue samples, a single breast cancer tissue sample showed heterozygosity at locus c.5834G>A within the ZFYVE26 gene (Zinc finger FYVE domain-containing gene 26).
CONCLUSIONS: Sjöblom et al./Wood et al. already showed that the vast majority of CAN-genes are mutated at very low frequency. Due to the fact that we only found one mutation in our cohort, we therefore assume that at the selected loci, mutations might be low-frequency events and therefore, more rarely detectable. However, further evaluation of the CAN-gene mutations in larger cohorts should be the aim of further studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691751     DOI: 10.1007/s00432-011-0990-4

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  15 in total

1.  A rapid and accurate approach to identify single nucleotide polymorphisms of mitochondrial DNA using MALDI-TOF mass spectrometry.

Authors:  Alex Xiu-Cheng Fan; Henk S P Garritsen; Shereen E L Tarhouny; Michael Morris; Sinuhe Hahn; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

Review 2.  p53 mutation heterogeneity in cancer.

Authors:  T Soussi; G Lozano
Journal:  Biochem Biophys Res Commun       Date:  2005-06-10       Impact factor: 3.575

3.  PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody.

Authors:  Antonia P Sagona; Ioannis P Nezis; Nina Marie Pedersen; Knut Liestøl; John Poulton; Tor Erik Rusten; Rolf I Skotheim; Camilla Raiborg; Harald Stenmark
Journal:  Nat Cell Biol       Date:  2010-03-07       Impact factor: 28.824

4.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

5.  High-throughput oncogene mutation profiling in human cancer.

Authors:  Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway
Journal:  Nat Genet       Date:  2007-02-11       Impact factor: 38.330

6.  Implications of the Human Genome Project for medical science.

Authors:  F S Collins; V A McKusick
Journal:  JAMA       Date:  2001-02-07       Impact factor: 56.272

7.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for genotyping of human platelet-specific antigens.

Authors:  Henk S P Garritsen; Alex Xiu-Cheng Fan; Nicole Bosse; Horst Hannig; Reinhard Kelsch; Hartmut Kroll; Wolfgang Holzgreve; Xiao Yan Zhong
Journal:  Transfusion       Date:  2008-10-29       Impact factor: 3.157

8.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Authors:  Tom Walsh; Silvia Casadei; Kathryn Hale Coats; Elizabeth Swisher; Sunday M Stray; Jake Higgins; Kevin C Roach; Jessica Mandell; Ming K Lee; Sona Ciernikova; Lenka Foretova; Pavel Soucek; Mary-Claire King
Journal:  JAMA       Date:  2006-03-22       Impact factor: 56.272

9.  The genomic landscapes of human breast and colorectal cancers.

Authors:  Laura D Wood; D Williams Parsons; Siân Jones; Jimmy Lin; Tobias Sjöblom; Rebecca J Leary; Dong Shen; Simina M Boca; Thomas Barber; Janine Ptak; Natalie Silliman; Steve Szabo; Zoltan Dezso; Vadim Ustyanksky; Tatiana Nikolskaya; Yuri Nikolsky; Rachel Karchin; Paul A Wilson; Joshua S Kaminker; Zemin Zhang; Randal Croshaw; Joseph Willis; Dawn Dawson; Michail Shipitsin; James K V Willson; Saraswati Sukumar; Kornelia Polyak; Ben Ho Park; Charit L Pethiyagoda; P V Krishna Pant; Dennis G Ballinger; Andrew B Sparks; James Hartigan; Douglas R Smith; Erick Suh; Nickolas Papadopoulos; Phillip Buckhaults; Sanford D Markowitz; Giovanni Parmigiani; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein
Journal:  Science       Date:  2007-10-11       Impact factor: 47.728

10.  Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.

Authors:  J Alsner; M Yilmaz; P Guldberg; L L Hansen; J Overgaard
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.